De audio van deze aflevering is mogelijk defect.
How to fix it?
OVER DEZE AFLEVERING
Listen to Tina Wang, Statistician, and Dr. Paul Schuette, Deputy Division Director, in the Office of Biostatistics Division of Analytics and Informatics within FDA’s Center for Drug Evaluation and Research discuss FDA’s experiences with a centralized statistical monitoring tool.
Engels
Verenigde Staten
OUDE AFLEVERINGEN ZOEKEN
Zoek naar eerdere afleveringen van FDA CDER Small Business and Industry Assistance (SBIA) Chronicles.
ANDERE AFLEVERINGEN IN DEZE PODCAST
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
Disclaimer: De podcast en de illustraties die op deze pagina zijn ingesloten, zijn afkomstig van U.S. Food and Drug Administration, Center for Drug Evaluation and Research, eigendom van de eigenaar en niet gelieerd aan of goedgekeurd door Listen Notes, Inc.
BEWERKEN
Bedankt voor uw hulp bij het up-to-date te houden van de podcast-database .
